Tang Eric C, Sobieszczyk Magdalena E, Shu Eileen, Gonzales Pedro, Sanchez Jorge, Lama Javier R
1 Columbia University College of Physicians and Surgeons , New York, New York.
AIDS Res Hum Retroviruses. 2014 May;30(5):416-24. doi: 10.1089/AID.2013.0212. Epub 2014 Jan 20.
Oral preexposure prophylaxis (PrEP) was the first biomedical intervention to demonstrate efficacy in preventing HIV infection among men who have sex with men (MSM). Healthcare providers' attitudes toward PrEP will be critical in translating this finding into effective public health rollout programs. In a convenience sample of 186 healthcare providers in Peru, we assessed knowledge, barriers, and attitudes to prescribe and monitor HIV PrEP for high-risk MSM and transgender women, the populations with the highest HIV incidence in this setting. A total of 57.5% reported awareness of PrEP, and awareness was independently associated with caring for more than 50 MSM (OR: 3.67, p<0.002). Lack of local guidelines, concern about increased high-risk behavior, antiretroviral drug resistance, and limited availability of antiretrovirals for HIV-infected individuals were the most common barriers to prescribing PrEP. Of all physicians 44.6% indicated that they would be likely to prescribe oral PrEP now; likelihood to prescribe was higher if PrEP were supported by local guidelines (70.3%, p<0.001), if more trials supported its effectiveness (68.5%, p<0.001), and if intermittent use were shown to be effective (62.2%, p=0.019). Physicians were more likely to prescribe PrEP now if they care for more than 50 MSM (OR: 6.62, p=0.010). Infectious disease specialists were less likely to prescribe PrEP (OR: 0.10, p=0.003) than nonspecialists. Successful large-scale implementation of PrEP in Peru will require focused educational campaigns to increase awareness and address concerns among healthcare providers.
口服暴露前预防(PrEP)是首个被证明对预防男男性行为者(MSM)感染艾滋病毒有效的生物医学干预措施。医疗服务提供者对PrEP的态度对于将这一发现转化为有效的公共卫生推广项目至关重要。在秘鲁186名医疗服务提供者的便利样本中,我们评估了他们对为高危男男性行为者和跨性别女性(该环境中艾滋病毒发病率最高的人群)开具和监测艾滋病毒PrEP的知识、障碍及态度。共有57.5%的人报告知晓PrEP,知晓情况与照顾超过50名男男性行为者独立相关(比值比:3.67,p<0.002)。缺乏当地指南、对高危行为增加的担忧、抗逆转录病毒药物耐药性以及艾滋病毒感染者抗逆转录病毒药物供应有限是开具PrEP最常见的障碍。在所有医生中,44.6%表示他们现在可能会开具口服PrEP;如果PrEP得到当地指南的支持(70.3%,p<0.001)、有更多试验支持其有效性(68.5%,p<0.001)以及间歇性使用被证明有效(62.2%,p=0.019),开具的可能性会更高。如果医生照顾超过50名男男性行为者,他们现在更有可能开具PrEP(比值比:6.62,p=0.010)。传染病专科医生比非专科医生开具PrEP的可能性更小(比值比:0.10,p=0.003)。要在秘鲁成功大规模实施PrEP,需要开展有针对性的教育活动,以提高医疗服务提供者的认识并解决他们的担忧。